James McCloskey, MD

home / authors / james-mccloskey-md

Articles

Patient Feedback for MDS: Insights and Closing Remarks
September 24th 2024

Patient Feedback for MDS: Insights and Closing Remarks

Ryan Haumschild, PharmD, MS, MBA James McCloskey, MD Amer Zeidan, MD Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Tracey Iraca

Medical experts offer their insights and closing remarks regarding patient feedback for MDS.

Oral vs. IV HMAs: Considerations and Patient Guidance
September 24th 2024

Oral vs. IV HMAs: Considerations and Patient Guidance

Ryan Haumschild, PharmD, MS, MBA James McCloskey, MD Amer Zeidan, MD Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Tracey Iraca

Medical experts discuss considerations and patient guidance for oral and IV HMAs.

Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact
September 17th 2024

Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

Ryan Haumschild, PharmD, MS, MBA James McCloskey, MD Amer Zeidan, MD Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Tracey Iraca

Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.

Innovations and Future Directions in Higher Risk MDS Treatments
September 17th 2024

Innovations and Future Directions in Higher Risk MDS Treatments

Ryan Haumschild, PharmD, MS, MBA James McCloskey, MD Amer Zeidan, MD Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Tracey Iraca

Medical experts discuss innovations and future directions in treatments for higher-risk MDS.

HMA Persistence and Effectiveness in Higher Risk MDS
September 10th 2024

HMA Persistence and Effectiveness in Higher Risk MDS

Ryan Haumschild, PharmD, MS, MBA James McCloskey, MD Amer Zeidan, MD Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Tracey Iraca

Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.

Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS
September 10th 2024

Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

Ryan Haumschild, PharmD, MS, MBA James McCloskey, MD Amer Zeidan, MD Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Tracey Iraca

Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.

ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
September 3rd 2024

ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

Ryan Haumschild, PharmD, MS, MBA James McCloskey, MD Amer Zeidan, MD Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Tracey Iraca

Medical experts discuss the data gathered from the ASCERTAIN trial.

Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
September 3rd 2024

Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

Ryan Haumschild, PharmD, MS, MBA James McCloskey, MD Amer Zeidan, MD Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Tracey Iraca

Medical experts offer insights on the COMMANDS trial findings.

Choosing MDS Therapies: Risk-Based Approaches
August 27th 2024

Choosing MDS Therapies: Risk-Based Approaches

Ryan Haumschild, PharmD, MS, MBA James McCloskey, MD Amer Zeidan, MD Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Tracey Iraca

Medical experts discuss risk-based approaches to choosing MDS therapies.

Advances in MDS Classification and Molecular Understanding
August 27th 2024

Advances in MDS Classification and Molecular Understanding

Ryan Haumschild, PharmD, MS, MBA James McCloskey, MD Amer Zeidan, MD Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Tracey Iraca

After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Hurricane | Image credit: Satoshi Kina - stock.adobe.com
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Opdivo packaging | Image credit: Bristol Myers Squibb
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
AJMC EBO logo | Image credit : AJMC
Published: November 1st 2024 | Updated: November 21st 2024
Table Multiple Myeloma Trials November 2024

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo